Plan to improve access to GP appointments for NHS patients

Together with the Department of Health and Social Care, NHS England has today published a blueprint for improving access to GP appointments for patients. GP surgeries will be provided with additional funding to boost their capacity for face-to-face appointments as part of a major drive to support general practice and improve performance. The funding will […]

read more

Shielding programme ends for the most vulnerable

Following expert clinical advice, the government is ending the requirement for shielding guidance for people considered to be clinically extremely vulnerable. Clinically extremely vulnerable people will not be advised to shield again, but might wish to take extra precautions to keep themselves safe, especially in areas of the country with high rates of infection. Read […]

read more

Most vulnerable people could be offered a COVID vaccine booster in September

The Joint Committee on Vaccination and immunisation (JVCI) have given interim advice on who to prioritise for a third dose of the COVID-19 booster vaccine from September. Millions of the most vulnerable people to COVID-19 may be offered the booster vaccination to ensure they have protection through the winter against new coronavirus variants. The JVCI’s […]

read more

Cellular signatures of kidney tumours

The origins of seven types of kidney cancer, including several rare subtypes, have been identified by researchers at the Wellcome Sanger Institute, Great Ormond Street Hospital (GOSH), the Princess Máxima Center for Paediatric Oncology and Oncode Institute. The findings confirm that these cancers originated in developmental cells found in the foetus. The results from the […]

read more

Overcoming misinformation in the diagnosis and treatment of kidney cancer

In this video interview from UroToday Dena Battle from KCCure, an American kidney cancer patient advocacy organisation, joins urologist Jaime Landman and oncologist Monty Pal to dispel common myths regarding the diagnosis and treatment of kidney cancer being observed in patient communities and to speak about what is driving this misinformation. Watch the video interview […]

read more

EIKCS 2021: Future treatments for metastatic kidney cancer

Despite the advances in first-line treatments for metastatic renal cell carcinoma (RCC) over the past few years, new treatments are on the horizon. In a presentation at the European International Kidney Cancer (EIKC) 2021 Virtual Annual Meeting, Dr Hans Hammers from University of Texas Southwestern Medical Center in the USA discussed future treatments for metastatic […]

read more

UK regulator confirms benefits of AstraZeneca vaccine far outweigh the risks

Following suspensions by some countries of the COVID-19 Oxford AstraZeneca COVID-19 vaccine over suspected blood clots, the Medicines and Healthcare Regulatory Authority (MHRA) in the UK confirms that the benefits of the vaccine in preventing COVID-19 far outweigh the risks. People should still go and get their COVID-19 vaccine when asked to do so. Read […]

read more

Cancer Research UK Cancer Patient Experience Survey

Cancer Research UK conducted a survey with cancer patients from across the UK to understand the impact of COVID-19 on their testing, treatment, and care, as well as their day-to-day lives and wellbeing. Nearly 2,000 people completed the survey in May 2020 to explore the impact of the COVID-19 pandemic on cancer patients. From this […]

read more

One Cancer Voice: Plotting a route out of the pandemic and towards world-leading cancer services

Governments across the UK have bold ambitions to improve cancer survival and transform patients’ quality of life for the 1 in 2 of us who will be diagnosed with the disease. Decades of hard work have resulted in cancer survival doubling over the last half a century – now half of people diagnosed with cancer […]

read more

HIF-2α inhibitor belzutifan to be fast-tracked for approval for VHL kidney cancer

Kidney cancers frequently have mutations in a gene called the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks […]

read more
Showing 1 to 10 of 272 results
  TOP